Xcout Intel
Alentis Therapeutics competitors & alternatives
The 12 closest competitors and alternatives to Alentis Therapeutics among biotechnology companies — ranked by similarity to what Alentis Therapeutics actually does, not by market-cap band.
Subscribe to see Alentis Therapeutics’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About Alentis Therapeutics
Alentis Therapeutics is a Swiss biotechnology company developing antibody-based medicines that target Claudin-1 (CLDN1), a protein involved in tumor biology and tissue fibrosis. Its therapies are intended for patients with solid tumors and fibrotic diseases, including liver and other organ fibrosis.
Alentis Therapeutics at a glance
Alentis Therapeutics is a biotechnology company headquartered in Switzerland. It has raised at least $248.4M across the 2 funding rounds on record. Its most recent funding round, Series D, raised $181.4M in November 2024. Xcout tracks 9 named people at Alentis Therapeutics, including Mark Pruzanski (Member, CEO).
Alentis Therapeutics leadership
- Mark PruzanskiMember, CEO
- Luca SantarelliChair
- Anna ChenMember
- Brian LiuMember
- Dina ChayaMember
- Naveed Siddiqi, MDMember
3 more named people on record for Alentis Therapeutics, with roles, board committees and tenure — see the full roster →
Alentis Therapeutics funding rounds
At least $248.4M raised across the 2 rounds on record. Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series D | $181.4M | 14 named | |
| — | $67M | 12 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Top 12 Alentis Therapeutics competitors
Ranked by semantic similarity — how close each company is to Alentis Therapeutics by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Similar biotechnology company
Galecto Biotech is a biotechnology company developing small-molecule inhibitors targeting galectin proteins and related pathways, with applications in fibrotic diseases and cancer. Its products are intended for patients and healthcare providers, particularly in areas with limited treatment options.
Similar biotechnology company
FibroGenesis is a U.S. biotechnology company focused on developing therapies for fibrosis and related fibrotic diseases. Its work is intended to serve patients with serious disorders in which excessive scar-tissue formation damages organs or tissues.
Biotech
AgomAb Therapeutics N.V. is a clinical-stage biopharmaceutical company dedicated to developing novel, disease-modifying therapies. Its primary focus lies in immunology and inflammatory ailments, particularly chronic fibrotic conditions where significant unmet medical needs persist. Its innovative pipeline features several promising candidates, including Ontunisertib (AGMB-129), an orally administered, gastrointestinal-restricted small molecule inhibitor targeting ALK5 or TGFßR1, designed to treat Fibrostenosing Crohn's disease and presently undergoing Phase 2a clinical trials. Also in development is AGMB-447, an inhaled small molecule that similarly inhibits ALK5 or TGFßR1, intended for idiopathic pulmonary fibrosis and currently in Phase 1 clinical studies. Furthermore, the company is advancing AGMB-101, a monoclonal antibody designed to mimic HGF. This agent exerts its effects through the agonism or stimulation of the MET receptor, having demonstrated both antifibrotic and regenerative capabilities in preclinical models. Established in 2017, AgomAb Therapeutics maintains its headquarters in Antwerp, Belgium.
Biotechnology / Life Science
Engitix is a biotechnology company that utilizes a proprietary platform based on human Extracellular Matrix (ECM) scaffolds to model and study disease biology. The company develops discovery-stage therapeutics targeting fibrosis, inflammation, and solid tumors, and forms partnerships with pharmaceutical and biotech organizations.
Similar biotechnology company
Certa Therapeutics is a private biotechnology company headquartered in Melbourne, Australia, focused on developing innovative precision therapies for the treatment of fibrotic diseases.
Similar biotechnology company
FNC Biotech is a biotechnology company established in 2021 that focuses on the development of antibody therapeutics for idiopathic pulmonary fibrosis and cancer.
Biotech
Numab Therapeutics is a Swiss biotechnology company developing multispecific antibody-based medicines that modulate immune-cell interactions. Its programs target serious diseases including cancer and immune-mediated or inflammatory disorders, serving patients through development and potential partnerships with pharmaceutical companies.
Similar biotechnology company
Vaderis Therapeutics AG is a clinical-stage biotechnology company focused on developing novel treatments for severe vascular diseases. The company is headquartered in Basel, Switzerland.
Similar biotechnology company
Mediar Therapeutics is a clinical-stage biotechnology company that develops novel antibody therapies to halt and reverse fibrotic diseases. The company focuses on deactivating myofibroblasts to treat conditions such as idiopathic pulmonary fibrosis (IPF), systemic sclerosis (SSc), and kidney fibrosis.
Similar biotechnology company
Pliant Therapeutics, Inc. is a biopharmaceutical company in the clinical development stage, dedicated to discovering, advancing, and bringing to market innovative therapies for fibrotic and related diseases across the United States. Its flagship investigational product, PLN-74809, is an orally administered, small-molecule, dual-selective inhibitor targeting both avß6 and avß1 integrins, which is currently progressing through three distinct Phase 2a clinical trials. The company's pipeline also includes PLN-1474, a small-molecule selective inhibitor of avß1, which has successfully completed its Phase 1 clinical assessment for treating liver fibrosis associated with nonalcoholic steatohepatitis (NASH). Furthermore, Pliant is nurturing two additional integrin-based initiatives in preclinical development: one focused on oncology, and another involving an allosteric agonistic monoclonal antibody designed to act upon an undisclosed integrin receptor for the treatment of various muscular dystrophies, including Duchenne muscular dystrophy. Founded in 2015, Pliant Therapeutics, Inc. maintains its corporate headquarters in South San Francisco, California.
Similar biotechnology company
Alchemab Therapeutics Ltd is a biotechnology company headquartered in London, England, focused on pioneering patient-centric antibody discovery and development.
Similar biotechnology company
Allink Biotherapeutics is a clinical-stage biotechnology company founded in 2023 and based in Shanghai, China, focused on developing advanced antibody-drug conjugates (ADCs) and therapeutics.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of Alentis Therapeutics and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for Alentis Therapeuticsand every competitor above — in one live dashboard.
Subscribe to Xcout Intel →